Follow-The-Filings

Security

AARD

Aardvark Therapeutics Inc. · COM

Equity holders as of 2026 Q1 (each manager’s latest book)

6 owners 2 new 2 exits max 0.0% (Vanguard Group Inc.)

grid → activity →
owners 6
max % 0.0%
tracked value $17M
qoq N 2 A 1 R 2 E 2

holders

sorted by % of portfolio · long equity only · exits show last held size

manager % port activity shares value history
Vanguard Group Inc. 2025 Q4 stale 0.0% Add 0.00 pp 717,430 $9M hist
Ken Griffin - Citadel Advisors LLC 2026 Q1 0.0% Reduce 0.00 pp 1,242,777 $5M hist
Two Sigma Investments, LP 2025 Q4 stale 0.0% Exit 0.00 pp 128,786 $2M hist
Cliff Asness - Aqr Capital Management LLC 2026 Q1 0.0% New 0.0% 134,495 $507 hist
Israel Englander - Millennium Management LLC 2026 Q1 0.0% Reduce 0.00 pp 98,334 $371 hist
Renaissance Technologies LLC 2026 Q1 0.0% New 0.0% 70,792 $267 hist
Steve Cohen - Point72 Asset Management, L.P. exited 2026 Q1 last 2025 Q4 0.0% Exit 0.00 pp 36,922 $485 hist
Dmitry Balyasny - Balyasny Asset Management L.P. exited 2026 Q1 last 2025 Q4 0.0% Exit 0.00 pp 13,817 $181 hist

6 current · 2 exited last period · options excluded

financials

US-GAAP annual · as tagged in Form 10-K · fiscal years · values link to the SEC filing

Income statement

Metric FY2025
Revenue $0.00
Gross profit —
Gross margin —
Net income -$57.59M
Net margin —

Balance sheet

Metric FY2025
Total current assets $111.89M
Total non-current assets * $5.3M
Total assets $117.18M
Total current liabilities $10.55M
Total non-current liabilities * $0.00
Total equity $106.63M

Cash flow

Metric FY2025
Cash from operations -$54.17M
Cash from investing -$49.67M
Cash from financing $89.25M
Net change in cash * -$14.59M

Source: SEC companyfacts (US-GAAP 10-K) · * = computed (not a single XBRL tag) · fiscal year as labeled by the issuer · not adjusted or audited by Follow-The-Filings

ownership over time

filing count by report period · click a bar for that quarter’s holders